Voyager Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Voyager Therapeutics şirketinin toplam hissedar öz sermayesi $330.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $426.0M ve $95.7M dir. Voyager Therapeutics 'in FAVÖK'ü $9.1M faiz karşılama oranı -0.5 dur. Şirketin $345.4M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-0.5x
Nakit	US$345.36m
Eşitlik	US$330.31m
Toplam yükümlülükler	US$95.73m
Toplam varlıklar	US$426.04m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VT6 'nin kısa vadeli varlıkları ( $373.4M ) kısa vadeli yükümlülüklerini ( $44.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: VT6 şirketinin kısa vadeli varlıkları ( $373.4M ) uzun vadeli yükümlülüklerini ( $51.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VT6 borçsuzdur.

Borcun Azaltılması: VT6 un 5 yıl önce borcu yoktu.

Borç Kapsamı: VT6 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: VT6 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Voyager Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.59 loss in 3Q 2023)

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 23%

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023)

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023)

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold €111k worth of stock

Investor sentiment improves as stock rises 17%

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022)

Investor sentiment improves as stock rises 27%

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

President recently sold €90k worth of stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New major risk - Shareholder dilution

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Investor sentiment improves as stock rises 26%

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings released: US$0.59 loss per share (vs US$0.46 profit in 3Q 2022)

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold €91k worth of stock

Second quarter 2023 earnings released: US$0.51 loss per share (vs US$0.50 loss in 2Q 2022)

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Investor sentiment deteriorates as stock falls 16%

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 19%

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022)

President recently sold €54k worth of stock

Chief Operating Officer recently sold €120k worth of stock

Full year 2022 earnings released: US$1.21 loss per share (vs US$1.89 loss in FY 2021)

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021)

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022

Second quarter 2022 earnings released: US$0.50 loss per share (vs US$0.80 loss in 2Q 2021)

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors

Voyager Therapeutics, Inc. Announces Executive Changes

Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction

Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting

First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.58 loss in 1Q 2021)

Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022

Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. Announces Executive Appointments

Third quarter 2021 earnings released: US$0.67 loss per share (vs US$2.30 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.66 loss in 1Q 2020)

Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.99 (vs US$1.21 loss in FY 2019)

Revenue misses expectations